Professor | Peichen Pan | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Peichen Pan
Contact Information	panpeichen@zju.edu.cn
Language ability	English, Chinese
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Peichen Pan

Contact Information

panpeichen@zju.edu.cn

Language ability

English, Chinese

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2021-present: Distinguished Researcher, Doctoral Supervisor, Zhejiang University 2019-2021: Postdoctoral Researcher, Harvard Medical School/Dana-Farber Cancer Institute (Co-supervisor: Prof. Jean Zhao) 2017-2019: Joint PhD Training, Harvard Medical School/Dana-Farber Cancer Institute (Supervisor: Prof. Jean Zhao) 2014-2019: PhD, Zhejiang University (Supervisor: Prof. Tingjun Hou) 2011-2014: Master's, Suzhou University (Supervisor: Prof. Tingjun Hou) 2007-2011: Bachelor's, Suzhou University (Supervisor: Prof. Tingjun Hou)
Work Experience	2021-present - Zhejiang University - Distinguished Researcher, Doctoral Supervisor 2019-2021 - Harvard Medical School/Dana-Farber Cancer Institute - Postdoctoral Researcher 2017-2019 - Harvard Medical School/Dana-Farber Cancer Institute - Joint PhD Training 2014-2019 - Zhejiang University - PhD Student 2011-2014 - Suzhou University - Master's Student 2007-2011 - Suzhou University - Bachelor's Student

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2021-present: Distinguished Researcher, Doctoral Supervisor, Zhejiang University
2019-2021: Postdoctoral Researcher, Harvard Medical School/Dana-Farber Cancer Institute (Co-supervisor: Prof. Jean Zhao)
2017-2019: Joint PhD Training, Harvard Medical School/Dana-Farber Cancer Institute (Supervisor: Prof. Jean Zhao)
2014-2019: PhD, Zhejiang University (Supervisor: Prof. Tingjun Hou)
2011-2014: Master's, Suzhou University (Supervisor: Prof. Tingjun Hou)
2007-2011: Bachelor's, Suzhou University (Supervisor: Prof. Tingjun Hou)

Work Experience

2021-present - Zhejiang University - Distinguished Researcher, Doctoral Supervisor
2019-2021 - Harvard Medical School/Dana-Farber Cancer Institute - Postdoctoral Researcher
2017-2019 - Harvard Medical School/Dana-Farber Cancer Institute - Joint PhD Training
2014-2019 - Zhejiang University - PhD Student
2011-2014 - Suzhou University - Master's Student
2007-2011 - Suzhou University - Bachelor's Student

Areas of Focus	Drug Screening Drug Design Pharmacology Medicinal Chemistry Cancer Biology Computational Biology
Publications	Discovery of Novel Inhibitors of BRD4 Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Network in Virtual Screening and Drug Design, Haiyang Zhong, Xinyue Wang, Shicheng Chen, Zhe Wang, Huating Wang, Lei Xu, Tingjun Hou, Xiaojun Yao, Dan Li, Peichen Pan, 2023 Efficient and accurate large library ligand docking with KarmaDock, Xujun Zhang, Odin Zhang, Chao Shen, Wanglin Qu, Shicheng Chen, Hanqun Cao, Yu Kang, Zhe Wang, Ercheng Wang, Jintu Zhang, Yafeng Deng, Furui Liu, Tianyue Wang, Hongyan Du, Langcheng Wang, Peichen Pan, Guangyong Chen, Chang-Yu Hsieh, Tingjun Hou, 2023 ML-PLIC: a web platform for characterizing protein-ligand interactions and developing machine learning-based scoring functions, Xujun Zhang, Chao Shen, Tianyue Wang, Yafeng Deng, Yu Kang, Dan Li, Tingjun Hou, Peichen Pan, 2023 A generalized protein–ligand scoring framework with balanced scoring, docking, ranking and screening powers, Chao Shen, Xujun Zhang, Chang-Yu Hsieh, Yafeng Deng, Dong Wang, Lei Xu, Jian Wu, Dan Li, Yu Kang, Tingjun Hou, Peichen Pan, 2023 Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis, Xing Zhang, Jianbo Tong, Tianhao Wang, Tianyue Wang, Lei Xu, Zhe Wang, Tingjun Hou, Peichen Pan, 2023 Proteome-Wide Profiling of the Covalent-Druggable Cysteines with a Structure-Based Deep Graph Learning Network, Hongyan Du, Dejun Jiang, Junbo Gao, Xujun Zhang, Lingxiao Jiang, Yundian Zeng, Zhenxing Wu, Chao Shen, Lei Xu, Dongsheng Cao, Tingjun Hou, Peichen Pan, 2022 Boosting Protein–Ligand Binding Pose Prediction and Virtual Screening Based on Residue–Atom Distance Likelihood Potential and Graph Transformer, Chao Shen, Xujun Zhang, Yafeng Deng, Junbo Gao, Dong Wang, Lei Xu, Peichen Pan, Tingjun Hou, Yu Kang, 2022 High-Throughput Glycolytic Inhibitor Discovery Targeting Glioblastoma by Graphite Dots–Assisted LDI Mass Spectrometry, Shi, R.; Pan, P.; Lv, R.; Ma, C.; Wu, E.; Guo, R.; Zhao, Z.; Song, H.; Zhou, J.; Liu, Y.; Xu, G.; Hou, T.; Kang, Z.; Liu, J., 2022 Combating drug-resistant mutants of ALK with potent and selective Type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation, Peichen Pan, Huidong Yu, Qinglan Liu, Xiaotian Kong, Hu Chen, Jiean Chen, Qi Liu, Dan Li, Yu Kang, Huiyong Sun, Wenfang Zhou, Sheng Tian, Sunliang Cui, Feng Zhu, Youyong Li, Yong Huang, Tingjun Hou, 2017 Structure-based Drug Design and Identification of H2O-soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in both Cancer and Lethal Inflammation Models In Vivo, Peichen Pan, Jiean Chen, Xijian Li, Miyang Li, Huidong Yu, Jean J Zhao, Jing Ni, Xuwen Wang, Huiyong Sun, Sheng Tian, Feng Zhu, Feng Liu, Yong Huang, Tingjun Hou, 2018 Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models, Peichen Pan, Huiyong Sun, Hui Liu, Dan Li, Wenfang Zhou, Xiaotian Kong, Youyong Li, Huidong Yu, Tingjun Hou, 2015 In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates, Peichen Pan, Huiyong Sun, Hui Liu, Dan Li, Wenfang Zhou, Xiaotian Kong, Youyong Li, Huidong Yu, Tingjun Hou, 2016 Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK), Kong, Xiaotian, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, Tingjun Hou, 2019 Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors, Chen, Changwei, Peichen Pan, Ziyang Deng, Dahai Wang, Qifan Wu, Lei Xu, Tingjun Hou, Sunliang Cui, 2019 Advances in the development of Rho-associated protein kinase (ROCK) inhibitors, Peichen Pan, Mingyun Shen, Huidong Yu, Youyong Li, Dan Li, Tingjun Hou, 2013 Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations, Peichen Pan, Lin Li, Youyong Li, Dan Li, Tingjun Hou, 2013 Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches, Peichen Pan, Youyong Li, Huidong Yu, Tingjun Hou, 2013 Constructing and Validating High-Performance MIEC-SVM Models in Virtual Screening for Kinases: A Better Way for Actives Discovery, Huiyong Sun, Peichen Pan, Sheng Tian, Lei Xu, Xiaotian Kong, Youyong Li, Dan Li, Tingjun Hou, 2016 Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays, Mingyun Shen, Sheng Tian, Peichen Pan, Huiyong Sun, Dan Li, Youyong Li, Hefeng Zhou, Chuwen Li, Simon Ming-Yuen Lee, Tingjun Hou, 2015 Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy, Li Y, Wang C, Xu T, Pan P, Yu Q, Xu L, Xiong X, Hou T, Cui S, Sun Y, 2021 Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes, Yu, Q., Hu, Z., Shen, Y., Jiang, Y., Peichen Pan, Hou, T., Pan, Z.-Q., Huang, J., Sun, Y., 2020 Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method, Liu, Z., Wang, Y., Kabraji, S., Xie, S., Peichen Pan, Liu, Z., Ni, J., Zhao, J. J., 2019 Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches, Sun, H., Duan, L., Chen, F., Liu, H., Wang, Z., Peichen Pan, Zhu, F., Zhang, J. Z. H., Hou, T., 2018 Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK, Kong, X., Sun, H., Peichen Pan, Zhu, F., Chang, S., Xu, L., Li, Y., Hou, T., 2018 Comparative analyses of structural features and scaffold diversity for purchasable compound libraries, Shang, J., Sun, H., Liu, H., Chen, F., Tian, S., Peichen Pan, Li, D., Kong, D., Hou, T., 2017 Discovery of a ROCK inhibitor, FPND, which prevents cerebral hemorrhage through maintaining vascular integrity by interference with VE-cadherin, Li, S., Ai, N., Shen, M., Dang, Y., Chong, C.-M., Peichen Pan, Kwan, Y. W., Chan, S. W., Leung, G. P. H., Hoi, M. P. M., Hou, T., Lee, S. M.-Y., 2017 How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

Areas of Focus

Drug Screening
Drug Design
Pharmacology
Medicinal Chemistry
Cancer Biology
Computational Biology

Publications

Discovery of Novel Inhibitors of BRD4 Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Network in Virtual Screening and Drug Design, Haiyang Zhong, Xinyue Wang, Shicheng Chen, Zhe Wang, Huating Wang, Lei Xu, Tingjun Hou, Xiaojun Yao, Dan Li, Peichen Pan, 2023
Efficient and accurate large library ligand docking with KarmaDock, Xujun Zhang, Odin Zhang, Chao Shen, Wanglin Qu, Shicheng Chen, Hanqun Cao, Yu Kang, Zhe Wang, Ercheng Wang, Jintu Zhang, Yafeng Deng, Furui Liu, Tianyue Wang, Hongyan Du, Langcheng Wang, Peichen Pan, Guangyong Chen, Chang-Yu Hsieh, Tingjun Hou, 2023
ML-PLIC: a web platform for characterizing protein-ligand interactions and developing machine learning-based scoring functions, Xujun Zhang, Chao Shen, Tianyue Wang, Yafeng Deng, Yu Kang, Dan Li, Tingjun Hou, Peichen Pan, 2023
A generalized protein–ligand scoring framework with balanced scoring, docking, ranking and screening powers, Chao Shen, Xujun Zhang, Chang-Yu Hsieh, Yafeng Deng, Dong Wang, Lei Xu, Jian Wu, Dan Li, Yu Kang, Tingjun Hou, Peichen Pan, 2023
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis, Xing Zhang, Jianbo Tong, Tianhao Wang, Tianyue Wang, Lei Xu, Zhe Wang, Tingjun Hou, Peichen Pan, 2023
Proteome-Wide Profiling of the Covalent-Druggable Cysteines with a Structure-Based Deep Graph Learning Network, Hongyan Du, Dejun Jiang, Junbo Gao, Xujun Zhang, Lingxiao Jiang, Yundian Zeng, Zhenxing Wu, Chao Shen, Lei Xu, Dongsheng Cao, Tingjun Hou, Peichen Pan, 2022
Boosting Protein–Ligand Binding Pose Prediction and Virtual Screening Based on Residue–Atom Distance Likelihood Potential and Graph Transformer, Chao Shen, Xujun Zhang, Yafeng Deng, Junbo Gao, Dong Wang, Lei Xu, Peichen Pan, Tingjun Hou, Yu Kang, 2022
High-Throughput Glycolytic Inhibitor Discovery Targeting Glioblastoma by Graphite Dots–Assisted LDI Mass Spectrometry, Shi, R.; Pan, P.; Lv, R.; Ma, C.; Wu, E.; Guo, R.; Zhao, Z.; Song, H.; Zhou, J.; Liu, Y.; Xu, G.; Hou, T.; Kang, Z.; Liu, J., 2022
Combating drug-resistant mutants of ALK with potent and selective Type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation, Peichen Pan, Huidong Yu, Qinglan Liu, Xiaotian Kong, Hu Chen, Jiean Chen, Qi Liu, Dan Li, Yu Kang, Huiyong Sun, Wenfang Zhou, Sheng Tian, Sunliang Cui, Feng Zhu, Youyong Li, Yong Huang, Tingjun Hou, 2017
Structure-based Drug Design and Identification of H2O-soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in both Cancer and Lethal Inflammation Models In Vivo, Peichen Pan, Jiean Chen, Xijian Li, Miyang Li, Huidong Yu, Jean J Zhao, Jing Ni, Xuwen Wang, Huiyong Sun, Sheng Tian, Feng Zhu, Feng Liu, Yong Huang, Tingjun Hou, 2018
Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models, Peichen Pan, Huiyong Sun, Hui Liu, Dan Li, Wenfang Zhou, Xiaotian Kong, Youyong Li, Huidong Yu, Tingjun Hou, 2015
In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates, Peichen Pan, Huiyong Sun, Hui Liu, Dan Li, Wenfang Zhou, Xiaotian Kong, Youyong Li, Huidong Yu, Tingjun Hou, 2016
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK), Kong, Xiaotian, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, Tingjun Hou, 2019
Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors, Chen, Changwei, Peichen Pan, Ziyang Deng, Dahai Wang, Qifan Wu, Lei Xu, Tingjun Hou, Sunliang Cui, 2019
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors, Peichen Pan, Mingyun Shen, Huidong Yu, Youyong Li, Dan Li, Tingjun Hou, 2013
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations, Peichen Pan, Lin Li, Youyong Li, Dan Li, Tingjun Hou, 2013
Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches, Peichen Pan, Youyong Li, Huidong Yu, Tingjun Hou, 2013
Constructing and Validating High-Performance MIEC-SVM Models in Virtual Screening for Kinases: A Better Way for Actives Discovery, Huiyong Sun, Peichen Pan, Sheng Tian, Lei Xu, Xiaotian Kong, Youyong Li, Dan Li, Tingjun Hou, 2016
Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays, Mingyun Shen, Sheng Tian, Peichen Pan, Huiyong Sun, Dan Li, Youyong Li, Hefeng Zhou, Chuwen Li, Simon Ming-Yuen Lee, Tingjun Hou, 2015
Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy, Li Y, Wang C, Xu T, Pan P, Yu Q, Xu L, Xiong X, Hou T, Cui S, Sun Y, 2021
Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes, Yu, Q., Hu, Z., Shen, Y., Jiang, Y., Peichen Pan, Hou, T., Pan, Z.-Q., Huang, J., Sun, Y., 2020
Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method, Liu, Z., Wang, Y., Kabraji, S., Xie, S., Peichen Pan, Liu, Z., Ni, J., Zhao, J. J., 2019
Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches, Sun, H., Duan, L., Chen, F., Liu, H., Wang, Z., Peichen Pan, Zhu, F., Zhang, J. Z. H., Hou, T., 2018
Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK, Kong, X., Sun, H., Peichen Pan, Zhu, F., Chang, S., Xu, L., Li, Y., Hou, T., 2018
Comparative analyses of structural features and scaffold diversity for purchasable compound libraries, Shang, J., Sun, H., Liu, H., Chen, F., Tian, S., Peichen Pan, Li, D., Kong, D., Hou, T., 2017
Discovery of a ROCK inhibitor, FPND, which prevents cerebral hemorrhage through maintaining vascular integrity by interference with VE-cadherin, Li, S., Ai, N., Shen, M., Dang, Y., Chong, C.-M., Peichen Pan, Kwan, Y. W., Chan, S. W., Leung, G. P. H., Hoi, M. P. M., Hou, T., Lee, S. M.-Y., 2017
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

Drug Screening Drug Design Pharmacology Medicinal Chemistry Cancer Biology Computational Biology Molecular Simulation Lead Compound Discovery Ai Technology Biophysics

Tingjun Hou - Zhejiang University

Yu Kang - Zhejiang University

Yingxia Li - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us